rhodamine 123 has been researched along with bortezomib in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, CY; Huang, FI; Huang, HL; Lai, MJ; Lee, HY; Li, YH; Liou, JP; Nepali, K; Yang, CR | 1 |
| Anderson, K; Clynes, M; Delmore, J; Jakubikova, J; Klippel, S; Meiller, J; Mitsiades, CS; O'Connor, R; O'Gorman, P; Ooi, MG; Richardson, P | 1 |
2 other study(ies) available for rhodamine 123 and bortezomib
| Article | Year |
|---|---|
(N-Hydroxycarbonylbenylamino)quinolines as Selective Histone Deacetylase 6 Inhibitors Suppress Growth of Multiple Myeloma in Vitro and in Vivo.
Topics: Animals; Antineoplastic Agents; Caco-2 Cells; Cell Proliferation; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Humans; Multiple Myeloma; Quinolines; Rats | 2018 |
The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Boronic Acids; Bortezomib; Cell Line; Cell Line, Tumor; Cellular Microenvironment; Coculture Techniques; Drug Resistance, Neoplasm; Fluorescent Dyes; Gene Expression Regulation; Humans; Multiple Myeloma; Pyrazines; Rhodamine 123; Stromal Cells | 2013 |